Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy
Clinical and Experimental Medicine · 2025
DOI: 10.1007/s10238-025-01934-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2025. Verfasst von Fabiana Letizia Cecere und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 2, IRCCS Regina Elena National Cancer Institute Rome, Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-met, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In patients with advanced non-small cell lung cancer (NSCLC), MET exon 14 ( MET ex14) skipping mutations are rare and are associated with a poor prognosis. Capmatinib, a selective oral MET inhibitor, was recently approved for the treatment of advanced MET ex14 skipping NSCLC. However, data from real-world experiences are limited. This was a retrospective analysis using real-world data from Italian patients with advanced MET ex14 skipping NSCLC who had received at least one treatment with immunotherapy and/or platinum-based chemotherapy and received compassionate use treatment with capmatinib. Patient characteristics, treatment details, discontinuations, and adverse events are reported. Overall, 53 patients received capmatinib after receiving treatment with immunotherapy and/or platinum-based chemotherapy in Italy. Patients had a median age of 74 years, mostly metastatic disease (92.5% of patients), and previously received one (66.0%) or more (2: 28.3%; 3: 5.7%) lines of standard treatment (immunotherapy and/or platinum-based chemotherapy). Most patients (98.1%) started treatment with capmatinib at the full recommended dose of 400 mg twice daily and 77.4% did not require a dose reduction. Twenty-four patients (45.3%) discontinued treatment; the most frequent reason for discontinuing treatment was disease progression, with a median estimated time to treatment discontinuation of 15.2 months. This real-world retrospective analysis confirms that capmatinib is a valuable treatment option for difficult-to-treat MET ex14 skipping NSCLC, in agreement with the data from the registration trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology 2, IRCCS Regina Elena National Cancer Institute Rome, Rome, Italy.
- Comprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
- Department of Oncology, University of Torino, AOU S. Luigi Gonzaga, Orbassano, Italy.
- Medical Oncology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Zitieren
APA
Cecere, F. L., D'Argento, E., Gelsomino, F., Pesola, F., Bironzo, P., Grisanti, S., Bonanno, L., Spitaleri, G., Valsecchi, D., Marcon, I., & Cortinovis, D. (2025). Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01934-2
Vancouver
Cecere FL, D'Argento E, Gelsomino F, Pesola F, Bironzo P, Grisanti S, et al. Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy. Clinical and Experimental Medicine. 2025. doi:10.1007/s10238-025-01934-2
BibTeX
@article{Cecere2025,
author = {Cecere, Fabiana Letizia and D'Argento, Ettore and Gelsomino, Francesco and Pesola, Francesco and Bironzo, Paolo and Grisanti, Salvatore and Bonanno, Laura and Spitaleri, Gianluca and Valsecchi, Diletta and Marcon, Ilaria and Cortinovis, Diego},
title = {Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy},
journal = {Clinical and Experimental Medicine},
year = {2025},
doi = {10.1007/s10238-025-01934-2}
}
EUVIMED